Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

DR. REDDY'S LABORATORIES LIMITED

🇱🇰Sri Lanka

Country: 🇱🇰Sri Lanka

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route

Phase 1

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Test Product
Drug: Reference product
Drug: Reference Medicinal Product

First Posted Date: 2023-11-13

Last Posted Date: 2023-11-13

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 330

Registration Number: NCT06126042

Locations: 🇺🇸
ICON, plc., Lenexa, Kansas, United States
🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
🇺🇸
ICON, Salt Lake City, Utah, United States

Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection

Phase 2

Conditions: COVID-19 Prevention

Interventions: Biological: Gam-COVID-Vac
Other: Placebo

First Posted Date: 2020-11-23

Last Posted Date: 2021-06-02

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 1600

Registration Number: NCT04640233

Locations: 🇮🇳
S N Medical College, Agra, India
🇮🇳
MGM Medical College and Hospital, Aurangabad, India
🇮🇳
KLE Prabhakar Kore Hospital, Belgaum, India

and more 20 locations

Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients

Phase 3

Terminated

Conditions: Covid19

Interventions: Drug: Placebo Comparator
Drug: AVIGAN

First Posted Date: 2020-08-27

Last Posted Date: 2022-03-21

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 353

Registration Number: NCT04529499

Locations: 🇰🇼
Jaber Al-Ahmad Al-Sabah Hospital (South Surra), Kuwait City, Kuwait
🇰🇼
Mishref Field Hospital (Mishref), Kuwait City, Kuwait

A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products

Phase 3

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2020-02-13

Last Posted Date: 2023-11-18

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 140

Registration Number: NCT04268771

Locations: 🇺🇸
Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, Arizona, United States
🇺🇸
California Allergy and Asthma Medical Group - CRN - PPDS 41230 11th Street West, Suite A, Palmdale, California, United States
🇺🇸
Inland Rheumatology Clinical Trials Incorporated, Upland, California, United States

and more 22 locations

Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma

Phase 3

Completed

Conditions: Follicular Lymphoma

Interventions: Biological: DRL_RI (Proposed rituximab biosimilar)
Other: MabThera®

First Posted Date: 2019-06-05

Last Posted Date: 2024-01-22

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 317

Registration Number: NCT03976102

Locations: 🇺🇸
The Oncology Institute of Hope and Innovation, Whittier, California, United States
🇺🇸
American Oncology Partners of Maryland, Bethesda, Maryland, United States
🇺🇸
University of Tennessee Medical Center - Cancer Institute, Knoxville, Tennessee, United States

and more 1 locations

Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg

First Posted Date: 2018-10-15

Last Posted Date: 2018-10-15

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 80

Registration Number: NCT03706300

Locations: 🇮🇳
QPS Bioserve India Pvt. Limited, Hyderabad, Telangana, India

Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tetrabenazine Tablets 25 mg

First Posted Date: 2018-10-11

Last Posted Date: 2018-10-11

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 48

Registration Number: NCT03702855

Locations: 🇮🇳
Accutest Research Laboratories (I) Pvt. Ltd., Navi Mumbai, Maharashtra, India

Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tetrabenazine Tablets 25 mg

First Posted Date: 2018-10-04

Last Posted Date: 2018-10-18

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 48

Registration Number: NCT03696329

Locations: 🇮🇳
Accutest Research Laboratories (I) Pvt. Ltd., Navi Mumbai, Maharashtra, India

A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris

Phase 2

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Tazarotene Cream, 0.1%
Drug: Tazarotene Lotion, 0.1%

First Posted Date: 2018-07-26

Last Posted Date: 2021-03-01

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 58

Registration Number: NCT03599193

Locations: 🇺🇸
Dr. DuBois, Austin, Texas, United States
🇺🇸
Dr. Jones, Austin, Texas, United States

Efficacy, Tolerability, Safety, and Pharmacokinetic Study of DFN-15

Phase 2

Completed

Conditions: Acute Pain

Interventions: Drug: Placebo
Drug: DFN-15 (Celecoxib Oral Solution) 62.5 mg
Drug: DFN-15 (Celecoxib Oral Solution) 125 mg
Drug: DFN-15 (Celecoxib Oral Solution) 250 mg

First Posted Date: 2018-06-13

Last Posted Date: 2021-01-22

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 120

Registration Number: NCT03554772

Locations: 🇺🇸
Site 101, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy